{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"title":"Complete response"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"}],"title":"Partial response"},{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"1"}],"title":"Stable disease"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}],"title":"Progressive disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"3"},{"groupId":"OG006","value":"2"}],"units":"Participants"}],"description":"Radiological assessments to evaluate disease extent (with change compared to nadir from the parent protocol) were performed at regular intervals, at a minimum once every 6 months or more frequently if clinically indicated (starting from their last scan on the parent protocol), per standard of care (SOC) at each facility. Tumor response was assessed by the Investigator as either complete response, partial response, stable disease, or progressive disease.","groups":[{"description":"Ganitumab 20 mg/kg once every 4 weeks by intravenous infusion.","id":"OG000","title":"20050118: Ganitumab 20 mg/kg"},{"description":"Conatumumab 0.45 mg/kg every 2 weeks by intravenous infusion.","id":"OG001","title":"20050171: Conatumumab 0.45 mg/kg"},{"description":"Conatumumab 3 mg/kg every 3 weeks by intravenous infusion.","id":"OG002","title":"20060295: Conatumumab 3 mg/kg"},{"description":"Conatumumab 5 mg/kg once every 3 weeks by intravenous infusion.","id":"OG003","title":"20060340: Conatumumab 5 mg/kg"},{"description":"Conatumumab 2 mg/kg once every 2 weeks by intravenous infusion in addition to modified FOLFOX6 chemotherapy and bevacizumab 5 mg/kg once every 2 weeks.","id":"OG004","title":"20060464: Conatumumab 2 mg/kg + mFOLFOX6 + Bevacizumab"},{"description":"Conatumumab 10 mg/kg once every 2 weeks by intravenous infusion in addition to modified FOLFOX6 chemotherapy, with or without bevacizumab 5 mg/kg once every 2 weeks.","id":"OG005","title":"20060464: Conatumumab 10 mg/kg + mFOLFOX6 ± Bevacizumab"},{"description":"Conatumumab 15 mg/kg + ganitumab 18 mg/kg once every 3 weeks by intravenous infusion.","id":"OG006","title":"20070411: Conatumumab 15 mg/kg + Ganitumab 18 mg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants who received at least one dose of conatumumab or ganitumab.","reportingStatus":"POSTED","timeFrame":"Approximately every 6 months until end of treatment; median duration of treatment with conatumumab was 1190.5 days and 1163.0 days for ganitumab.","title":"Best Overall Response","type":"SECONDARY","unitOfMeasure":"Participants"}